Immuno-Biological Laboratories Co., Ltd. has signed a collaboration and license agreement with IBL International GmbH. The agreement has been mutually signed by both parties for commercializing of in vitro diagnostics, or IVD, products for use in Alzheimer disease, or AD. The IVD product enables to quantitatively measure Amyloidbeta protein which deeply involves with AD.

IBL-Japan has been focusing on R&D of antibodies and ELISA kits which specifically detect Amyloidbeta protein which consist the plaques appear in the brains of individuals who suffers AD patients for over decades. By entering this agreement, IBL-Japan will license out of the antibodies and supply the critical materials to IBL-Int'l for commercializing of the IVD products and IBL-Int'l will have the right for selling the commercialized IVD products worldwide.